Market ExpansionAlpha Cognition is eligible to receive royalties on net sales of ZUNVEYL in Asia, Australia, and New Zealand, which are not factored into the current valuation and may drive upside.
Product AdoptionOver 50% of prescribers have already written refill prescriptions for ZUNVEYL, indicating strong early adoption.
Regulatory ApprovalChinese regulatory submission accepted for review by the National Medical Products Administration, potentially leading to approval next year.